{"id":"rifapentine-rpt","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Drug interactions (enzyme induction)"}]},"_chembl":{"chemblId":"CHEMBL1660","moleculeType":"Small molecule","molecularWeight":"877.04"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rifapentine is a rifamycin antibiotic that binds to the bacterial RNA polymerase enzyme and blocks RNA synthesis in mycobacteria. It has a longer half-life than rifampicin, allowing for less frequent dosing. It is bactericidal against Mycobacterium tuberculosis and is used as part of combination therapy for tuberculosis.","oneSentence":"Rifapentine inhibits bacterial RNA polymerase, preventing transcription and killing or stopping the growth of mycobacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:08.541Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (TB), including drug-susceptible and latent TB infection"},{"name":"Pulmonary tuberculosis as part of combination therapy"}]},"trialDetails":[{"nctId":"NCT07124559","phase":"PHASE1, PHASE2","title":"A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-05-15","conditions":"Tuberculosis","enrollment":144},{"nctId":"NCT05411744","phase":"PHASE4","title":"One-month Latent Tuberculosis Treatment for Renal Transplant Candidates","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-07-01","conditions":"Latent Tuberculosis, End Stage Renal Disease, Renal Transplant Candidate for Right Kidney","enrollment":25},{"nctId":"NCT05122026","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2024-01-17","conditions":"HIV Seropositivity, Pregnancy, Tuberculosis Infection","enrollment":252},{"nctId":"NCT06917495","phase":"PHASE2","title":"Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shandong University","startDate":"2025-04-05","conditions":"Mild Spinal Tuberculosis","enrollment":300},{"nctId":"NCT06191692","phase":"PHASE3","title":"1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam","status":"NOT_YET_RECRUITING","sponsor":"Freundeskreis Für Internationale Tuberkulosehilfe e.V","startDate":"2025-08-01","conditions":"Tuberculosis Infection","enrollment":350},{"nctId":"NCT03785106","phase":"PHASE3","title":"Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals","status":"ACTIVE_NOT_RECRUITING","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2019-08-15","conditions":"HIV-infected Participants With Latent TB Infection in High TB Burden Country","enrollment":2500},{"nctId":"NCT01582711","phase":"PHASE3","title":"Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2012-09","conditions":"Latent Tuberculosis Infection","enrollment":1002},{"nctId":"NCT06281834","phase":"PHASE1","title":"Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-11-15","conditions":"Pediatric HIV Infection, Latent Tuberculosis","enrollment":25},{"nctId":"NCT03474029","phase":"PHASE2, PHASE3","title":"Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI","status":"RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2019-08-01","conditions":"Latent Tuberculosis","enrollment":3400},{"nctId":"NCT04272242","phase":"PHASE2","title":"Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-02-27","conditions":"HIV Infection, LTBI","enrollment":37},{"nctId":"NCT00023452","phase":"PHASE3","title":"Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2001-06","conditions":"Tuberculosis","enrollment":8053},{"nctId":"NCT03510468","phase":"PHASE1","title":"Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2018-06-12","conditions":"Healthy Volunteers","enrollment":51},{"nctId":"NCT04094012","phase":"PHASE3","title":"Risk of SDRs Under 3HP and 1HP Regimen for LTBI","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2019-09-24","conditions":"Latent Tuberculosis Infection","enrollment":490},{"nctId":"NCT03266991","phase":"PHASE4","title":"Treatment of Latent Tuberculosis in Socially Marginalised Citizens","status":"TERMINATED","sponsor":"Aarhus University Hospital","startDate":"2017-10-27","conditions":"Compliance, Patient","enrollment":22},{"nctId":"NCT04600167","phase":"PHASE3","title":"Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus","status":"UNKNOWN","sponsor":"Dr. Nyanda Elias Ntinginya","startDate":"2022-06-17","conditions":"Diabetes Mellitus, Tuberculosis","enrollment":3000},{"nctId":"NCT02771249","phase":"PHASE1","title":"Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2016-06-03","conditions":"HIV Infected Population With Latent Tuberculosis","enrollment":37},{"nctId":"NCT01574638","phase":"PHASE1","title":"Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-06","conditions":"Tuberculosis","enrollment":44},{"nctId":"NCT01404312","phase":"PHASE3","title":"Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-05-23","conditions":"Tuberculosis, HIV Infections","enrollment":3000},{"nctId":"NCT02651259","phase":"PHASE1, PHASE2","title":"Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-03-13","conditions":"Tuberculosis","enrollment":50},{"nctId":"NCT02430259","phase":"PHASE3","title":"Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2015-03","conditions":"Silicosis, Tuberculosis","enrollment":566},{"nctId":"NCT03886701","phase":"PHASE1","title":"Doravirine, Rifapentine and Isoniazid Interaction","status":"COMPLETED","sponsor":"Walter K. Kraft","startDate":"2019-04-22","conditions":"Latent Tuberculosis, Human Immunodeficiency Virus, Rifamycins Causing Adverse Effects in Therapeutic Use","enrollment":11},{"nctId":"NCT01162486","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2010-04","conditions":"Tuberculosis, Tuberculosis, Pulmonary","enrollment":37},{"nctId":"NCT03900858","phase":"NA","title":"Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis(SCRIPT-TB)","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2018-12-01","conditions":"Silicosis Tuberculosis","enrollment":566},{"nctId":"NCT00814671","phase":"PHASE2","title":"Study of Daily Rifapentine for Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2010-04","conditions":"Tuberculosis","enrollment":153}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Priftin","Rifamycin"],"phase":"phase_3","status":"active","brandName":"Rifapentine (RPT)","genericName":"Rifapentine (RPT)","companyName":"Walter K. Kraft","companyId":"walter-k-kraft","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifapentine inhibits bacterial RNA polymerase, preventing transcription and killing or stopping the growth of mycobacteria. Used for Tuberculosis (TB), including drug-susceptible and latent TB infection, Pulmonary tuberculosis as part of combination therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}